Evidence map›Paper›PMID 39312544›Full record

ArticlePloS one2024

Matrix metalloproteinases mediate influenza A-associated shedding of the alveolar epithelial glycocalyx.

Kaitlyn R Schaaf, Stuart R Landstreet, Nathan D Putz, Samantha K Gonski, Jason Lin, Charity J Buggs, Dustin Gibson, Christophe J Langouët-Astrié, Christopher S Jetter, Nicolas M Negretti and 5 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kaitlyn R SchaafVanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0002-8473-6642
Stuart R LandstreetDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Nathan D PutzDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Samantha K GonskiDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Jason LinDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Charity J BuggsDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Dustin GibsonDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Christophe J Langouët-AstriéDivision of Pulmonary and Critical Care, Department of Medicine, University of Colorado Anschutz, Denver, Colorado, United States of America.
Christopher S JetterDepartment of Neonatology, Monroe Caroll Children's Hospital at Vanderbilt, Nashville, Tennessee, United States of America.
Nicolas M NegrettiDepartment of Neonatology, Monroe Caroll Children's Hospital at Vanderbilt, Nashville, Tennessee, United States of America.
Jennifer M S SucreDepartment of Neonatology, Monroe Caroll Children's Hospital at Vanderbilt, Nashville, Tennessee, United States of America.
Eric P SchmidtDivision of Pulmonary and Critical Care, Department of Medicine, University of Colorado Anschutz, Denver, Colorado, United States of America.
Lorraine B WareDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Julie A BastaracheDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Ciara M ShaverDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

Funding

Interdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3M
Applying Innovative Lung Mapping Strategies to Understand Alveolar Capillary Barrier Permeability in ARDSR35HL150783 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2020 to 2026
$4.6M
Immunogenomic analysis of donor lung injury and its impact on clinical outcomes after lung transplantationR01HL160551 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ciara M Shaver · 2022 to 2026
$3.4M
Integrated Molecular and Cellular Drivers of AlveologenesisR01HL168556 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jennifer MalcolmSrygley Sucre · 2023 to 2026
$2.8M
Haptoglobin 2 variant and endothelial glycocalyx shedding in sepsis-induced ARDSR01HL158906 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WARE, LORRAINE B · 2021 to 2024
$2.3M
Wnt Signaling in Bronchopulmonary DysplasiaK08HL143051 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SUCRE, JENNIFER MALCOLMSRYGLEY · 2019 to 2023
$698k
NHLBI NIH HHS K08 HL143051NHLBI NIH HHS R01 HL158906NHLBI NIH HHS R01 HL160551NHLBI NIH HHS R01 HL168556NHLBI NIH HHS R35 HL150783NHLBI NIH HHS T32 HL094296
6 · The paper itself

Abstract

backgroundThe alveolar epithelium is protected by a heparan sulfate-rich, glycosaminoglycan layer called the epithelial glycocalyx. It is cleaved in patients with acute respiratory distress syndrome (ARDS) and in murine models of influenza A (IAV) infection, shedding fragments into the airspace from the cell surface. Glycocalyx shedding results in increased permeability of the alveolar-capillary barrier, amplifying acute lung injury. The mechanisms underlying alveolar epithelial glycocalyx shedding in IAV infection are unknown. We hypothesized that induction of host sheddases such as matrix metalloproteinases (MMPs) during IAV infection results in glycocalyx shedding and increased lung injury. MATERIALS AND

methodsWe measured glycocalyx shedding and lung injury during IAV infection with and without treatment with the pan-MMP inhibitor Ilomastat (ILO) and in an MMP-7 knock out (MMP-7KO) mouse. C57BL/6 or MMP-7KO male and female mice were given IAV A/PR/8/34 (H1N1) at 30,000 PFU/mouse or PBS intratracheally. For some experiments, C56BL/6 mice were infected in the presence of ILO (100mg/kg) or vehicle given daily by IP injection. Bronchoalveolar lavage (BAL) and lung tissue were collected on day 1, 3, and 7 for analysis of glycocalyx shedding (BAL Syndecan-1) and lung injury (histology, BAL protein, BAL cytokines, BAL immune cell infiltrates, BAL RAGE). Expression and localization of the sheddase MMP-7 and its inhibitor TIMP-1 was examined by RNAScope. For in vitro experiments, MLE-12 mouse lung epithelial cells were cultured and treated with active or heat-inactivated heparinase (2.5 U/mL) prior to infection with IAV (MOI 1) and viral load and MMP-7 and TIMP-1 expression analyzed.

resultsIAV infection caused shedding of the epithelial glycocalyx into the BAL. Inhibition of MMPs with ILO reduced glycocalyx shedding by 36% (p = 0.0051) and reduced lung epithelial injury by 40% (p = 0.0404). ILO also reduced viral load by 68% (p = 0.027), despite having no significant effect on lung cytokine production. Both MMP-7 and its inhibitor TIMP-1 were upregulated in IAV infected mice: MMP-7 colocalized with IAV, while TIMP-1 was limited to cells adjacent to infection. However, MMP-7KO mice had similar glycocalyx shedding, epithelial injury, and viral load compared to WT littermates, suggesting redundancy in MMP sheddase function in the lung. In vitro, heparinase treatment before infection led to a 52% increase in viral load (p = 0.0038) without altering MMP-7 or TIMP-1 protein levels.

conclusionsGlycocalyx shedding and MMPs play key roles in IAV-induced epithelial injury, with significant impact on IAV viral load. Further studies are needed to understand which specific MMPs regulate lung epithelial glycocalyx shedding.

Indexed as

GlycocalyxMatrix Metalloproteinase 7Mice, Inbred C57BLOrthomyxoviridae InfectionsAnimalsFemaleHydroxamic AcidsIndolesInfluenza A Virus, H1N1 SubtypeMaleMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiceMice, KnockoutPulmonary AlveoliTissue Inhibitor of Metalloproteinase-1Hydroxamic AcidsilomastatIndolesMatrix Metalloproteinase 7Matrix Metalloproteinase InhibitorsMatrix MetalloproteinasesTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID39312544
PMCPMC11419339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.